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We report the case of a 76-year-old man who was diagnosed as having chronic myeloid leukemia (CML) with p190 BCR-ABL
while receiving treatment for symptomatic multiple myeloma (MM). ,e diagnosis of MM was based on the presence of serum
M-protein, abnormal plasma cells in the bone marrow, and lytic bone lesions. ,e patient achieved a partial response to
lenalidomide and dexamethasone treatment. However, 2 years after the diagnosis of MM, the patient developed leukocytosis with
granulocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed Philadelphia chromosomes and chimeric
p190 BCR-ABL mRNA. Fluorescence in situ hybridization also revealed BCR-ABL-positive neutrophils in the peripheral blood,
which suggested the emergence of CMLwith p190 BCR-ABL. ,e codevelopment of MM and CML is very rare, and this is the ﬁrst
report describing p190 BCR-ABL-type CML coexisting with MM. Moreover, we have reviewed the literature regarding the
coexistence of these diseases.
1. Introduction
Multiple myeloma (MM) is a lymphoid cancer that is
characterized by monoclonal proliferation of malignant
plasma cells in the bone marrow, monoclonal protein in the
serum, and organ dysfunction [1]. Chronic myeloid leu-
kemia (CML) is a clonal disorder of myeloid origin that is
characterized by the Philadelphia chromosome, t(9; 22)
(q34; q11), in which the BCR-ABL fusion gene is created.
Several types of BCR-ABL are known, with the p210 and
p190 types being the most common, distinguished by the
break point in the BCR gene.,e vast majority of CML cases
result from the p210-type of BCR-ABL, while the p190-type
is rarely found in CML [2].,e coexistence of MM and CML
in the same patient is rare, with only 22 reported cases
[3–23], all involving p210 BCR-ABL. ,erefore, we report
a case of coexisting MM and CML with p190 BCR-ABL.
Given the rarity of this case, we also discuss the origins of
these hematologic malignancies and review the relevant
literature.
2. Case Report
A 76-year-old man was referred to our hospital in September
201X, because of right leg pain, lower back pain,
and weight loss of 3 kg. Lumbar magnetic resonance im-
aging and computed tomography (CT) suggested the
presence of lumbar spinal canal stenosis and a sacral tumor
(Figure 1(a)). Laboratory testing revealed a markedly el-
evated serum IgG level (5,436mg/dL, normal: 800–
1,800mg/dL) and an elevated serum beta-2 microglobulin
level (4.1 µg/mL, normal: 0–3 µg/mL), although there were
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no signs of anemia, renal dysfunction, or proteinuria.
Serum immunoﬁxation revealed IgGκ-type M-protein,
with an estimated serum-free κ and λ chain ratio of 21.5 : 1
(Figure 1(b)). Microscopic examination and ﬂow cytometric
analysis of bone marrow aspirate revealed elevated numbers
of CD138-positive abnormal plasma cells. Cytogenetic
analysis of the bone marrow revealed 46XY, and the patient
was diagnosed as havingMM (R-ISS, stage II). Chimeric p190
BCR-ABL mRNA was not detected in the bone marrow
sample at this point. ,e patient underwent two cycles of
bortezomib plus dexamethasone and two cycles of
cyclophosphamide, bortezomib, and dexamethasone (CBD)
but did not respond to either treatment regimen. ,e
treatment was switched to lenalidomide (25mg/day) plus
dexamethasone (20mg/week; Ld therapy), and there was
a marked response, with a substantial decrease in the
M-protein and disappearance of the sacral tumor on CT.
After 24 cycles of Ld therapy, the patient achieved a partial
response based on the International Myeloma Working
Group criteria.
In December 201X+2, the patient developed leukocytosis
(white blood cell count: 35.8 × 109/L) and thrombocytopenia
(a) (b)
Figure 1: (a) Computed tomography (CT) at the time of multiple myeloma (MM) diagnosis. Sacral tumor and lytic bone involvement in the
lumbar spine are shown (arrow). (b) Serum immunoﬁxation at the time of MM diagnosis. SP, size marker; G IgG; A IgA; M IgM; κ, kappa
chain; λ, lambda chain.
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Figure 2: (a) Karyotype from a bone marrow specimen at the time of chronic myeloid leukemia (CML) diagnosis. t(9; 22) is shown by using
arrows. (b) Fluorescence in situ hybridization for peripheral blood cells. Arrowheads, BCR-ABL fusion gene (yellow); large arrows, ABL
signal (red); small arrows, BCR signal (green). (c) Polymerase chain reaction (PCR) ampliﬁcation analysis from the bone marrow specimen
taken at the time of CML diagnosis. Lane 1, size marker; lane 2, p210 negative control; lane 3, p190 negative control; lane 4, p210 positive
control; lane 5, p190 positive control; lane 6, p210 patient’s sample; lane 7, p190 patient’s sample.
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Table 1: Concomitant multiple myeloma and chronic myeloid leukemia cases.
Pt Age/Sex Year Firstdisease
Diagnosis
interval
(month)
Type of
M-protein
,erapy for
MM
,erapy for
CML
Conﬁrmation
method of Ph+
Type
of Ph Reference
1 77M 1972 MM 33 BJP No treatment Notreatment Chr
MacSween and
Langley [3]
2 65/F 1974 CML 113 IgG-κ No treatment Busulfan Chr Derghazarian andWhittemore [4]
3 58/M 1982
MM
and
CML
Simultaneous IgG-κ MP, RT HU,Busulfan, Chr Boots and Pegrum[5]
4 71/M 1993 MM 24 IgG-κ MP, RT HU Chr Klenn et al. [6]
5 72/F 1998
MM
and
CML
Simultaneous IgG-κ VP IFN-α Chr, PCR, FISH P210 Tanaka et al. [7]
6 70/M 1999 MM 33 IgG-κ Not reported Notreported Chr Nitta et al. [8]
7 81/M 2001
MM
and
CML
Simultaneous IgA-κ MP Notreatment Chr, PCR Alvarez-Larránet al. [9]
8 66/M 2003
MM
and
CML
Simultaneous IgG-κ MP INF-α, HU,Busulfan Chr, PCR, FISH P210 Schwarzmeier et al.[10]
9 47/M 2003 MM 33 BJP LOAD-IN Notreported Chr Nakagawa [11]
10 68/M 2005 CML 20 IgG-λ MP IFN-α,imatinib Chr, PCR P210 Garipidou et al. [12]
11 85/F 2005
MM
and
CML
Simultaneous IgG-λ Not reported Notreported Chr, PCR P210
Wakayama et al.
[13]
12 76/M 2009 CML 14 IgA-κ MP IFN-α,imatinib Chr, PCR, FISH P210 Galanopoulos et al.[14]
13 57/F 2009 CML 65 IgA-κ TD, VAD Imatinib Chr, PCR P210 Michael et al. [15]
14 72/F 2010 CML 3 IgG-κ No treatment Imatinib Chr, PCR P210 Ide et al. [16]
15 71/F 2012
MM
and
CML
Simultaneous IgG-κ MP, Bd, Ld Imatinib Chr Oﬃah et al. [17]
16 64/F 2013
MM
and
CML
Simultaneous IgA-κ BD Imatinib Chr Romanenko et al.[18]
17 62/F 2013 MM 17 IgG-κ RT, VCD,VCDD, VRD Dasatinib Chr, PCR P210 Ragupathi et al. [19]
18 77/M 2014
MM
and
CML
Simultaneous IgG-κ RT, BD Notreatment Chr, PCR P210 Maerki et al. [20]
19 60/M 2014 MM 48 IgG-κ RT, Ld HU,dasatinib Chr, FISH Alsidawi et al. [21]
20 63/F 2012 CML 120 IgG-κ BD, Ld Imatinib Chr, PCR P210 Pessach et al. [22]
21 68/M 2012 MM 54 IgG-λ VAD Imatinib Chr, PCR P210 Pessach et al. [22]
22 76/M 2015 CML 38 IgA-λ No treatment Imatinib Chr, PCR Ahn et al. [23]
23 51/F 2016 MM Unknown IgG BD Imatinib Chr, PCR Wolleschak andHeidel [24]
24 88/M 2016
MM
and
CML
Simultaneous IgD-κ VRD Imatinib Chr Ali et al. [25]
25 76/M 2018 MM 28 IgG-κ Ld Dasatinib,bosutinib Chr, PCR, FISH P190 Our case
BJP, Bence Jones protein; MP, melphalan, prednisolone; RT, radiation therapy; HU, hydroxyurea; LOAD-IN, melphalan, ranimustine, vincristine, IFN-α;
PSL, prednisolone; VCD, bortezomib, cyclophosphamide, dexamethasone; VCDD, VCD plus doxorubicin; VRD, bortezomib, lenalidomide, dexamethasone;
Ld, lenalidomide, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; CBD, BD plus cyclophosphamide; Rd,
lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; Chr, chromosome; PCR, polymerase chain reaction; FISH, ﬂuorescence in situ
hybridization.
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(platelet count: 3 × 109/L). Bone marrow biopsy and aspi-
ration revealed hypercellularity with a marked increase in
myeloid lineage cells but without an increase in blast cells
(4%). Cytogenetic analysis revealed 46XY t(9; 22) (q34;
q11.2) in 20 of 20 cells, and ﬂuorescence in situ hybridization
(FISH) analysis revealed that 99.5% of the cells were positive
for BCR-ABL. Peripheral blood neutrophils were also pos-
itive for BCR-ABL (98.8%) (Figures 2(a)–2(b)). Chimeric
p190, but not p210, BCR-ABL mRNA was detected by using
polymerase chain reaction (Figure 2(c)). ,e diagnosis was
conﬁrmed to be CML with p190 BCR-ABL in the accelerated
phase (AP), which coexisted with MM (a maintained partial
response). Dasatinib treatment (100mg/day) was started
immediately. ,e dose was subsequently decreased to
50mg/day, due to the persistence of thrombocytopenia. In
April 201X+3, a bone marrow examination indicated that
the patient had achieved a second chronic phase, with 31% of
this cells being positive for BCR-ABL upon FISH analysis,
and that his peripheral blood count had normalized.
However, 5 months later, FISH analysis revealed that 85.8%
of his bone marrow cells were positive for BCR-ABL, and
subsequently, his treatment was changed from dasatinib to
bosutinib. ,is switch appeared to be ineﬀective, as no
decrease in the BCR-ABL-positive bone marrow cells was
detected after 2 months.
3. Discussion
,ere have only been 24 cases of coexisting MM and CML
reported (Table 1) [3–25]. MM and CML were diagnosed
simultaneously in 9 cases, and the diagnoses were sequential
in the remaining cases, with MM being diagnosed ﬁrst in 8
cases and CML being diagnosed ﬁrst in 7 cases. Among the
previous reports, all genotypes conﬁrmed by PCR were
p210-CML in patients with coexisting MM and CML. Our
case is the ﬁrst reported ofMM coexisting with p190-CML in
the same patient. ,e intervals between the sequential di-
agnoses ranged from 3 months to 120 months. Multiple
possibilities could be considered regarding the association
between MM and CML. First, these two malignancies could
occur independently, and their coexistence, while very rare,
could be simply coincidence. Second, common precursors,
referred to as “clonal hematopoiesis of indeterminate po-
tential (CHIP),” give rise to both MM and CML cells in
a patient. Given our patient’s relatively advanced age, it is
possible that CHIP had a common origin, although we have
no direct evidence to support this possibility. A third pos-
sible explanation is that the second disease might be
a therapy-related malignancy that develops after treatment
for the ﬁrst disease. In the present case, the diagnosis of MM
was followed by that of CML. ,e frequency of secondary
carcinogenesis in patients with MM was evaluated for co-
horts participating in clinical trials with lenalidomide, which
were conducted from 2000 through 2012 [24]. ,is report
showed that the incidence of secondary hematologic ma-
lignancies was increased in patients who concurrently re-
ceived melphalan and lenalidomide, while it did not increase
in those receiving other treatment protocols, regardless of
whether lenalidomide was included [26]. ,ere is no clear
evidence that lenalidomide is carcinogenic, and there has
only been one reported case of CML that developed after
lenalidomide treatment. ,erefore, the increased incidence
of hematologic malignancies has been attributed to mel-
phalan, because alkylating agents such as melphalan are
known to cause therapy-related myelodysplastic syndromes.
According to previous case reports of MM coexisting with
CML, many patients received alkylating agents as treatment
for MM (Table 1). In the present case, a small dose of an
alkylating agent (cyclophosphamide; total: 2,400mg/m2)
was administered during two cycles of CBD therapy. We,
therefore, needed to consider the possibility that the cy-
clophosphamide treatment caused the CML. However, an
accumulation of case reports and further investigations are
required to draw deﬁnitive conclusions.
Although p190 BCR-ABL CML has been reported in 1%
of CML cases, there have been several clinical observations
suggesting that CML with p190 BCR-ABL is diﬃcult to treat
[27]. Furthermore, p190 BCR-ABL has been identiﬁed as
a marker for high-risk disease, and early stem cell trans-
plantation has been recommended if the patient is eligible
[26]. Our patient received initial treatment of dasatinib for
his CML in AP with p190 BCR-ABL, which provided
a partial cytogenetic response at 4 months after the di-
agnosis. Although the long-term eﬀects of dasatinib treat-
ment in patients with p190 BCR-ABL CML are unknown, in
the present case, the duration of response to dasatinib was
relatively short.
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